Abstracts tagged "psoriatic arthritis and rheumatoid arthritis (RA)"

Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
M. Elaine Husni¹, Vandana Rai², Marcia Leon Rabanal³ and Unnikrishnan Chandrasekharan⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…
Abstract Number: 2524 • 2017 ACR/ARHP Annual Meeting
Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis
Alexis Ogdie¹, Michael D. George², Joel Gelfand³, Maureen Dubreuil⁴, Thorvardur Love⁵ and Joshua Baker⁶, ¹Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania Health System , Philadelphia, PA, ⁴Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Landspitali University Hospital, Reykjavik, Iceland, ⁶Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) has been associated with weight loss around the time of diagnosis; little is known about weight change around diagnosis in…
Abstract Number: 2170 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Risk in Patients with Psoriasis, Psoriatic and Rheumatoid Arthritis: A Prospective Study Using Secured Anonymised Information Technology Databank in Wales, United Kingdom
Ernest H. Choy¹, Roxanne Cooksey², Sinead Brophy², Jonathan Kennedy², Fabiola Fernandez-Gutierrez³, Ruth Davies⁴, Timothy Pickles⁵ and Vincent Piguet⁶, ¹CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom, ²College of Medicine, Swansea University, Swansea, United Kingdom, ³Cancer Research UK Manchester Institute, Manchester, United Kingdom, ⁴CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁵CREATE Center, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ⁶Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Compared with cardiovascular (CV) risk in rheumatoid arthritis (RA), precise CV risk in psoriatic arthritis (PsA) and psoriasis is less established, particularly the relative…
Abstract Number: 2442 • 2016 ACR/ARHP Annual Meeting
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis
Neda Amiri¹, Gretchen Bandoli², Diana L Johnson² and Christina D. Chambers², ¹Division of Rheumatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pediatrics, University of California, San Diego, La Jolla, CA
Use of Nonsteroidal Anti-inflammatory Drugs in Pregnant Women with Inflammatory Arthritis Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are generally contraindicated in the third trimester of pregnancy…
Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting
Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Philip Mease¹, Manish Mittal², Martha Skup², Matthew Davis³, Arijit Ganguli², Scott Johnson³ and Michael Schiff⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴University of Colorado, Greenwood Village, CO
Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
Abstract Number: 100 • 2016 ACR/ARHP Annual Meeting
Patient Support Program for Adalimumab-Treated Patients in Brazil: Impact on Patients’ Adherence and Persistence
Roger A. Levy¹, Vanessa Teich², Roberta Fernandes², Anna Gulart², Leonardo Chaves³, Vishvas Garg⁴ and Martha Skup⁵, ¹Rheumatology, Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Sense Company, São Paulo, Brazil, ³AbbVie Inc., Chicago, IL, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: The Brazilian public healthcare system covers treatment with adalimumab for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriatic arthritis, in line with local guidelines.…
Abstract Number: 537 • 2016 ACR/ARHP Annual Meeting
Differences and Associated Factors in General Disability and Hand Disability Between Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Jose Andres Roman Ivorra¹, Óscar Álvarez¹, Jose Ivorra Cortes¹, Javier Navarro Muñoz², Elena Grau Garcia³, Luis Gonzalez Puig¹, Inmaculada Chalmeta Verdejo¹, Carlos Feced Olmos¹, Eztizen Labrador Sanchez¹, Francisco Miguel Ortiz-Sanjuán⁴, Karla Arevalo Ruales¹, Rosa Negueroles Albuixech¹, Jorge Fragio Gil¹, Isabel Martinez Cordellat¹, Jose Luis Valero Sanz¹, Cristina Alcañiz Escandell^1,3, Gema Poveda Marin^1,3, Carmen Najera Herranz¹ and Victoria Fornes Ferrer⁵, ¹Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Universidad Católica de Valencia, Valencia, Spain, ³IIS La Fe, Valencia, Spain, ⁴Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Santander, Spain, ⁵Biostatistics Unit. IIS La Fe, Valencia, Spain
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are well-known disabling conditions, with high impact on patients functioning and quality of life. However, little is…
Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting
Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients
Alejandro Balsa¹, Raimon Sanmarti², José Rosas³, Susana Gomez Castro⁴, Ana Cabez⁴, Victor Martin⁴ and María Montoro⁴, ¹Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴Pfizer, Madrid, Spain
Abstract Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients. Background/Purpose: The treatment of…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 1481 • 2016 ACR/ARHP Annual Meeting
Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases
Silvia Rollefstad, Pia Norheim, Eirik Ikdahl and Anne Grete Semb, Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The excess risk of cardiovascular disease (CVD) in patients with inflammatory joint diseases (IJD) is attributable to several risk factors, including a high prevalence…
Abstract Number: 1555 • 2016 ACR/ARHP Annual Meeting
E-Comorbidity: Evaluation of the Validity of Electronic Comorbidity Assessment in Identifying Comorbid Conditions Among Patients with Rheumatoid and Psoriatic Arthritis
Yasser M. El Miedany¹, Maha El Gaafary^2,3, Sally Youssef⁴, Sami Bahlas⁵, Mohammed Hegazi⁶ and Ihab Ahmed⁷, ¹Rheumatology, Darent Valley Hospital, Dartford, United Kingdom, ²Community, Environmental and Occupational Medicine, Ain Shams University, Abbassia, Egypt, ³Community, Environmental and Occupational Medicine, Ain Shams University, Cairo, Egypt, ⁴Rheumatology and Rehabilitation Departmennt, Ain Shams University, Cairo, Egypt, ⁵Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁶Medicine, Al Adan Hospital, Kuwait, Kuwait, ⁷Medicine, Cairo University, Cairo, Egypt
Background/Purpose: 1. to assess the validity of an electronically comorbidity assessment strategy to identify comorbid conditions among RA and PsA patients in standard practice. 2.…
Abstract Number: 1658 • 2016 ACR/ARHP Annual Meeting
Regulatory Role of the IL-9/IL-9R System on Pannus Formation in Psoriatic Arthritis
Siba P. Raychaudhuri^1,2 and Smriti K. Raychaudhuri³, ¹Davis, CA, ²Rheumatology, Univ of California, Davis & VAMC Sacramento, Davis, CA, ³Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA
Background/Purpose: Earlier we have reported that synovial tissues of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are enriched with the Th9 cells along…
Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Lauren Harter¹, Daniel Shin², Joshua F. Baker³, Junko Takeshita², Thorvardur Love^4,5, Joel Gelfand⁶ and Alexis Ogdie⁷, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵Landspitali University Hospital, Reykjavík, Iceland, ⁶University of Pennsylvania Health System , Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
Abstract Number: 30 • 2015 ACR/ARHP Annual Meeting
Complications of Inflammatory Arthritis in First Nations and Non-First Nations Populations of Alberta, Canada
Cheryl Barnabe¹, Gilaad Kaplan², J Antonio Avina-Zubieta³, Diane Lacaille⁴, Brenda Hemmelgarn⁵ and JM Esdaile⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ³Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Centre, University of British Columbia, Vancouver, BC, Canada, ⁵Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁶Rheumatology, Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: With markedly improved control of the acute effects of inflammatory arthritis, the major causes of morbidity and premature death now arise from the complications…
Abstract Number: 192 • 2015 ACR/ARHP Annual Meeting
Comparison of Bone Scan with Xiralite (FOI) in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
Joerg Polter, Susanne Drynda and Jörn Kekow, Clinic for Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: In recent years Xiralite, an ICG-enhanced fluorescence optical imaging (FOI) technology, has gained growing importance as a non-radioactive imaging technique for the detection of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].